Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Bifidobacterium longum subsp. longum remodeled Roseburia and Phosphatidylserine levels, meliorated intestinal disorders and liver metabolic abnormalities induced by high-fat diet.

  • 2020-04-02
  • Journal of Agricultural and Food Chemistry 68(16)
    • Tao Wu
    • Mengzhen Sun
    • R. Liu
    • Wenjie Sui
    • Jiaojiao Zhang
    • Jinjin Yin
    • Jiangu Zhu
    • S. Fang
    • Min Zhang

Abstract

Bifidobacterium longum is considered as a potential supplement in antiobesity treatment; however, the underlying molecular mechanism has rarely been studied. To understand the contributions of B. longum subsp. longum (BL21) in the prevention of obesity, we investigated alterations in the liver metabonomic phenotype and gut microbiota by ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry and 16S ribosomal RNA gene sequencing in C57BL/6J male mice orally administered with BL21 for 8 weeks [high-fat diet (HFD)]. BL21 at 1 × 109 CFU·day-1 per mouse reduced the weight of mice by 16.9% relative to that of the mice fed with HFD and significantly lowered the serum levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol. BL21 also ameliorated fat vacuolization in liver cells and epididymal fat accumulation. BL21 also lowered the Firmicutes/Bacteroidetes ratio, regulated liver remodeling in glycerophospholipids, and alleviated the levels of d-tryptophan. A positive correlation between the butyrate-producing strain Roseburia and the cell membrane component phosphatidylserine was found for the first time. Thus, BL21 can potentially prevent mice from being obese by rebalancing the gut microbiota and glycerophospholipid metabolism. BL21 can be a promising dietary supplement for weight control.

Keywords: Bifidobacterium longum subsp. longum; gut microbiota; liver metabonomic; obesity.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium longum B1-05Balanced Gut MicrobiotaBeneficial
Moderate
Bifidobacterium longum B1-05Reduced Body WeightBeneficial
Large
Bifidobacterium longum B1-05Reduced Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum B1-05Reduced D-Tryptophan LevelsBeneficial
Small
Bifidobacterium longum B1-05Reduced Hepatic Fat AccumulationBeneficial
Moderate
Bifidobacterium longum B1-05Regulated Liver Glycerophospholipid MetabolismBeneficial
Moderate
Bifidobacterium longum BL03Improved Glycerophospholipid MetabolismBeneficial
Moderate
Bifidobacterium longum BL03Improved Liver FunctionBeneficial
Moderate
Bifidobacterium longum BL03Improved Microbiota BalanceBeneficial
Moderate
Bifidobacterium longum BL03Reduced Body WeightBeneficial
Large
Bifidobacterium longum BL03Reduced Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum MAK34B12LOptimized Gut Microbiota CompositionBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced Liver Fat VacuolizationBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced Weight GainBeneficial
Moderate
Bifidobacterium longum MAK34B12LRegulated Liver Glycerophospholipid MetabolismBeneficial
Moderate
Bifidobacterium longum Rosell-175Improved Liver FunctionBeneficial
Moderate
Bifidobacterium longum Rosell-175Reduced Body WeightBeneficial
Large
Bifidobacterium longum Rosell-175Reduced Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEAlleviated D-Tryptophan LevelsBeneficial
Small
Bifidobacterium longum Rosell-175 MEImproved Glycerophospholipid MetabolismBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEReduced Body WeightBeneficial
Large
Bifidobacterium longum Rosell-175 MEReduced Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEReduced Epididymal Fat MassBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEReduced LDL CholesterolBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEReduced Liver Fat VacuolizationBeneficial
Moderate
Bifidobacterium longum Rosell-175 MEReduced Serum Triglyceride LevelsBeneficial
Moderate
Bifidobacterium longum subsp. longumBalanced Gut MicrobiotaBeneficial
Moderate
Bifidobacterium longum subsp. longumImproved Glycerophospholipid MetabolismBeneficial
Moderate
Bifidobacterium longum subsp. longumImproved Liver FunctionBeneficial
Moderate
Bifidobacterium longum subsp. longumReduced Body WeightBeneficial
Large
Bifidobacterium longum subsp. longumReduced Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum subsp. longumReduced D-Tryptophan LevelsBeneficial
Small
Bifidobacterium longum subsp. longum 35624Alleviated D-Tryptophan LevelsBeneficial
Small
Bifidobacterium longum subsp. longum 35624Improved Gut Microbiota BalanceBeneficial
Moderate
Bifidobacterium longum subsp. longum 35624Reduced Body WeightBeneficial
Large
Bifidobacterium longum subsp. longum 35624Reduced Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum subsp. longum 35624Reduced Liver Fat VacuolizationBeneficial
Moderate
Bifidobacterium longum subsp. longum 35624Regulated Liver Glycerophospholipid MetabolismBeneficial
Moderate
Bifidobacterium longum subsp. longum UABI-14Improved Gut Microbiota BalanceBeneficial
Moderate
Bifidobacterium longum subsp. longum UABI-14Reduced Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum subsp. longum UABI-14Reduced Liver Fat VacuolizationBeneficial
Moderate
Bifidobacterium longum subsp. longum UABI-14Reduced Weight GainBeneficial
Moderate
Bifidobacterium longum UABl-14Improved Gut Microbiome CompositionBeneficial
Moderate
Bifidobacterium longum UABl-14Reduced Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum UABl-14Reduced Liver FatBeneficial
Moderate
Bifidobacterium longum UABl-14Reduced Weight GainBeneficial
Moderate
Back to top